Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687)

Birincil Dil	İngilizce
Bölüm	Makaleler
Yazarlar	G. Atassi Bu kişi benim A. Pierre Bu kişi benim N. Guilbaud Bu kişi benim L. Kraus-berthier Bu kişi benim D. Saint-dizier Bu kişi benim E. Bisagni Bu kişi benim
Yayımlanma Tarihi	30 Mart 2015
Yayımlandığı Sayı	Yıl 1995 Cilt: 11 Sayı: 1-2

Kaynak Göster

APA	Atassi, G., Pierre, A., Guilbaud, N., Kraus-berthier, L., vd. (2015). Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687). Marmara Pharmaceutical Journal, 11(1-2), 141-150. https://doi.org/10.12991/mpj.61492
AMA	Atassi G, Pierre A, Guilbaud N, Kraus-berthier L, Saint-dizier D, Bisagni E. Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687). mpj. Nisan 2015;11(1-2):141-150. doi:10.12991/mpj.61492
Chicago	Atassi, G., A. Pierre, N. Guilbaud, L. Kraus-berthier, D. Saint-dizier, ve E. Bisagni. “Preclinical Antitumor Activity of a Novel Olivacine Derivative: S 16020-2 (NSC-659687)”. Marmara Pharmaceutical Journal 11, sy. 1-2 (Nisan 2015): 141-50. https://doi.org/10.12991/mpj.61492.
EndNote	Atassi G, Pierre A, Guilbaud N, Kraus-berthier L, Saint-dizier D, Bisagni E (01 Nisan 2015) Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687). Marmara Pharmaceutical Journal 11 1-2 141–150.
IEEE	G. Atassi, A. Pierre, N. Guilbaud, L. Kraus-berthier, D. Saint-dizier, ve E. Bisagni, “Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687)”, mpj, c. 11, sy. 1-2, ss. 141–150, 2015, doi: 10.12991/mpj.61492.
ISNAD	Atassi, G. vd. “Preclinical Antitumor Activity of a Novel Olivacine Derivative: S 16020-2 (NSC-659687)”. Marmara Pharmaceutical Journal 11/1-2 (Nisan 2015), 141-150. https://doi.org/10.12991/mpj.61492.
JAMA	Atassi G, Pierre A, Guilbaud N, Kraus-berthier L, Saint-dizier D, Bisagni E. Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687). mpj. 2015;11:141–150.
MLA	Atassi, G. vd. “Preclinical Antitumor Activity of a Novel Olivacine Derivative: S 16020-2 (NSC-659687)”. Marmara Pharmaceutical Journal, c. 11, sy. 1-2, 2015, ss. 141-50, doi:10.12991/mpj.61492.
Vancouver	Atassi G, Pierre A, Guilbaud N, Kraus-berthier L, Saint-dizier D, Bisagni E. Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687). mpj. 2015;11(1-2):141-50.